Double-blind comparison of moclobemide and tranylcypromine in depression.

  title={Double-blind comparison of moclobemide and tranylcypromine in depression.},
  author={Gerhard Heinze and L Rossel and I Gabelic and J Galeano-Munoz and M. Stabl and Steven R. Allen},
  volume={26 6},
Moclobemide is the first of a new generation of reversible inhibitors of monoamine oxidase-A (RIMA) with no clinically relevant potentiation of the hypertensive actions of dietary tyramine. The present study was conducted to compare the efficacy and safety of moclobemide with an established irreversible monoamine oxidase inhibitor, tranylcypromine, in depressed patients. Patients were randomized to receive moclobemide (81 patients) or tranylcypromine (79 patients) at individually titrated doses… CONTINUE READING